A2734

α5IA

≥98% (HPLC)

• Synonyme(s) : 1,2,4-Triazolo[3,4-a]phthalazine, 3-(5-methyl-3-isoxazolyl)-6-[(1-methyl-1H-1,2,3-triazol-4-yl)methoxy]-, 3-(5-Methylisoxazol-3-yl)-6-(1-methyl-1,2,3-triazol-4-yl)methoxy-1,2,4-triazolo[3,4-a]phthalazine
• Formule empirique (notation de Hill): C₁₇H₁₄N₈O₂
• Numéro CAS: 215874-86-5
• Poids moléculaire : 362.35
• Numéro MDL: MFCD09832717
• Code UNSPSC : 12352200
• ID de substance PubChem : 329770794
• Nomenclature NACRES : NA.77

Propriétés

• Pureté: ≥98% (HPLC)
• Forme: powder
• Couleur: off-white to light yellow
• Solubilité: DMSO: >2 mg/mL
• Auteur: Merck & Co., Inc., Kenilworth, NJ, U.S.
• Température de stockage: 2-8°C
• Chaîne SMILES: Cc1cc(no1)-c2nnc3c4ccccc4c(OCc5cn(C)nn5)nn23
• InChI: 1S/C17H14N8O2/c1-10-7-14(22-27-10)16-20-19-15-12-5-3-4-6-13(12)17(21-25(15)16)26-9-11-8-24(2)23-18-11/h3-8H,9H2,1-2H3
• Clé InChI: NZMJFRXKGUCYNP-UHFFFAOYSA-N

Description

Actions biochimiques/physiologiques

α5IA is a selective inverse agonist for Α5 subtype of GABAA receptor with a higher intrinsic activity at the A5 subtype than other drugs. α5IA enhances cognition in laboratory animals without being proconvulsant or anxiogenic. α5IA acts as an "alcohol antagonist," markedly reducing the amnesic effect of alcohol and partially attenuating sedation, similar to Ro15-4513, but without the anxiogenic effect. α5IA offers promise as a tool to study cognitive disorders, memory function, and treatment of alcohol-related disorders.

Caractéristiques et avantages

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informations sur la sécurité

• Code de la classe de stockage: 13 - Non Combustible Solids
• Classe de danger pour l'eau (WGK): WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable
• Équipement de protection individuelle: Eyeshields, Gloves, type N95 (US)